Showing results (431-440 of 577) with videos related to

Sort By:
Pageof 58
BMC Cancer|March 21, 2023
ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C)Susanna Slater, Annette Bryant, Hsiang-Chi Chen, et al.
European Journal of Cancer (Oxford, England : 1990)|January 27, 2022
Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma - A comparison of the FLOT and 'MAGIC' regimensJonathan L Moore, Sacheen Kumar, Aida Santaolalla, et al.
BMC Cancer|April 26, 2023
Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centreDavid K Lau, Caroline Fong, Faten Arouri, et al.
Current Oncology (Toronto, Ont.)|April 21, 2022
Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC StudyFiona Turkes, Annette Bryant, Ruwaida Begum, et al.
Journal of Hepatology|May 25, 2020
Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancerMairéad Geraldine McNamara, Andre Lopes, Harpreet Wasan, et al.
The Lancet. Oncology|April 13, 2013
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trialRoger D James, Robert Glynne-Jones, Helen M Meadows, et al.
Cancers|May 27, 2026
Total Neoadjuvant Approach for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma-UK Tertiary Cancer Centre ExperienceKai Tai Derek Yeung, Simon Gomberg, William Hodgson, et al.
The New England Journal of Medicine|June 2, 2025
Perioperative Durvalumab in Gastric and Gastroesophageal Junction CancerYelena Y Janjigian, Salah-Eddin Al-Batran, Zev A Wainberg, et al.
The Lancet. Haematology|April 30, 2025
Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trialMichael Northend, William Wilson, Kushani Ediriwickrema, et al.
The Lancet. Oncology|March 8, 2014
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trialKirit M Ardeshna, Wendi Qian, Paul Smith, et al.
Pageof 58